Efficacy of cannabidiol in improving the quality of life with Parkinson’s Patient: integrative review





Cannabidiol; Quality of Life; Parkinson Disease; Therapeutic uses.


Objective: To investigate the applicability and benefits of cannabidiol therapy in improving the quality of life of patients with Parkinson's disease. Methodology: This is an integrative literature review where articles were selected using the platforms of BIREME, SCIENCE, EBSCO, PUBMED, LILACS and only complete articles in Portuguese, English and German and published among 1995 to 2020. Results: Given the facts, this article brought the effectiveness of cannabidiol for the treatment of first choice for Parkinson's disease, and to promote patients and their families a better coexistence with the disease, and positive effects in all areas for a better quality of life. Conclusion: Although cannabidiol has shown efficacy in the therapy of parkinsonian patients, the need for further studies and investigations regarding its therapeutic effects is still evident. Thus, cannabidiol could become the treatment of choice for PD, and promote better coexistence with the disease for patients and their families.


Aarsland D., Ballard C., Walker Z., Bostrom F., Alves G., Kossakowski K., Leroi I., Pozo-Rodriguez F., Minthon L. & Londos E. (2009). Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol.

Barbosa, E. R. & Sallem F. A. S. (2005). Doença de Parkinson. Revista neurociências, 13(3), 158-165.

Baronep, E. R., & Picillo M. (2017).Quality of Life and Nonmotor Symptoms in Parkinson's Disease. Int Rev Neurobiol; 133:499-516.

Bruck, S. (2015). Cannabinoids in neurology–Brazilian Academy of Neurology. Arquivos de neuro-psiquiatria, 73 (4), 371-374.

Campbell. (2014). W.W. DeJong: O exame Neurológico. 7° edição. Guanabara Koogan Ltda.

Chagas, M. H. N. (2014). Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. Journal of Psychopharmacology, 28 (11), 1088-1098.

Crippa, J. A.S.; Zuardi, A. W., H., & Jaime E.C. (2010). Uso terapêutico dos canabinoides em psiquiatria. Brazilian Journal of Psychiatry, 32, 556-566.

Deiana S, W. A, Yamasaki Y., Amada N., Arthur M., Fleming S., Woodcock H., Dorward P., Pigliacampo B., Close S., Platt B., & Riedel G. (2012). Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl).

Dos Santos, R. G.; Hallak, J. E. C & Crippa, J. A. S. (2019). O uso do Canabidiol (CBD) no tratamento da Doença de Parkinson e suas comorbidades. Revista de Medicina, 98 (1), 46-51.

Gurgel, H. L. C. (2019). Uso terapêutico do canabidiol: a demanda judicial no estado de Pernambuco, Brasil. Saúde e Sociedade, 28, 283-295.

Iannott, F. A.; Di M V. & Petrosino S. (2016). Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. Progress in lipid research, 62, 107-128.

Katz M, G. Y. & Kluger B. M. (2018). Top Ten Tips Palliative Care Clinicians Should Know About Parkinson's Disease and Related Disorders. J Palliat Med.

Kluger, B., Triolo, P., Jones W. & Jankovic, J. - The Therapeutic Potential of Cannabinoids for Movement Disorders. HHS Public.

Martins, C. C. M., Caon, G., Moraes, & Chaiane M. O. (2020). A Doença de Parkinson e o Processo de Envelhecimento Motor: uma Revisão de Literatura. Saúde e Desenvolvimento Humano, 8 (3) 155-167.

Mcpartland, John M. (2015). Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. British journal of pharmacology, 172 (3), 737-753.

Peres, F. F. (2016). Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats. Frontiers in pharmacology, 7, 343.

Rocha, M. S. G. (2015). Discinesias induzidas por levodopa em 176 pacientes com doença de Parkinson. Arq. Neuro-Psiquiatr. São Paulo, 53 (4), 737-742.

Santos, E A. G. (2015). The neuroprotection of cannabidiol against MPP+-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease. Toxicology in Vitro, 30 (1), 231-240.

Shohet, A. (2017). Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson's disease. European Journal of Pain, 21 (3), 486-493.

Souza, C. F. M. (2011). A Doença de Parkinson e o processo de envelhecimento motor. Revista Neurociências, 19 (4), 718-723.

Sunaga, B. Y. (2018). Efeitos terapêuticos e tóxicos da Cannabis sativa. Trabalho de Conclusão de Curso (Graduação em Farmácia) - Universidade Federal de São Paulo - Campus Diadema.

Woo, Y., Hyun, M. K.. (2019). Effectiveness of Integrative Therapy for Parkinson’s Disease Management. Frontiers in aging neuroscience, 11, 40.

Sousa, L. M. M. S., Marques-Vieira, C. M. A., Severino, S. S., & Antunes, A. V. (2017). Metodologia de revisão integrativa da literatura em enfermagem.



How to Cite

SILVA, M. T. .; SOUZA, E. L. .; FONSECA, M. M. de P. da .; MIRANDA, W. S. P. .; VENTURA RODRIGUES, R. . Efficacy of cannabidiol in improving the quality of life with Parkinson’s Patient: integrative review . Research, Society and Development, [S. l.], v. 10, n. 13, p. e09101320768, 2021. DOI: 10.33448/rsd-v10i13.20768. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/20768. Acesso em: 3 dec. 2021.



Health Sciences